Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

141.44 -1.11 (-0.78%)
Official Closing Price Updated: 4:10 PM EDT, Aug 17, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,604,160
Open 141.42
Bid (Size) 141.52 (3)
Ask (Size) 142.40 (4)
Prev. Close 142.55
Today's Range 140.55 - 142.76
52wk Range 105.56 - 175.91
Shares Outstanding N/A
Dividend Yield 3.68%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
This Analyst Cuts I-Mab's Price Target By 43%
I-Mab (NASDAQ: IMAB) reported significant changes to the company's collaboration on developing CD47 targeting agents.  
Via Benzinga
Why Blue Water Vaccines Is Trading Higher By Around 80%, Here Are 61 Stocks Moving In Wednesday's Mid-Day Session
Gainers Blue Water Vaccines, Inc. (NASDAQ: BWV) shares jumped 79.5% to $4.57 after the company announced it plans to explore the potential development of a novel monkeypox vaccine using its norovirus... 
Via Benzinga

Performance

YTD
+4.45%
+4.45%
1 Month
-5.44%
-5.44%
3 Month
-8.62%
-8.62%
6 Month
-2.29%
-2.29%
1 Year
+19.45%
+19.45%

More News

Read More
Looking At AbbVie's Recent Whale Trades
Via Benzinga
AbbVie, Sosei Build In 2020 Pact With New Neurological Disease-Focused Agreement
Via Benzinga
6 Analysts Have This to Say About AbbVie
Via Benzinga
AbbVie Calls Off Early-Stage Trial For I-Mab's CD47-Targeted Blood Cancer Candidate
Via Benzinga
180 Life Sciences: Why Investors Should Take Notice
Via Talk Markets
ABBVIE INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of AbbVie Inc. - ABBV
From Kahn Swick & Foti, LLC
Via Business Wire
Here's How Much You Would Have Made Owning AbbVie Stock In The Last 5 Years
Via Benzinga
This Nasal Spray For Eye Disease Stock Is 'Attractive', Has Potential 160% Upside
Via Benzinga
NYSE:ABBV Long Term Shareholder Notice: Investigation of Potential Wrongdoing at AbbVie Inc.
Via SBWire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
7 Blue-Chip Stocks That Will Survive 2022
Via InvestorPlace
Are Medtronic And Intuitive Surgical Poised For Big Growth?
Via MarketBeat
Topics ETFs
Exposures COVID-19
The 3 Best Vanguard Funds to Buy in August
Via InvestorPlace
The 7 Most Undervalued Value Stocks to Buy Now
Via InvestorPlace
Two Appealing Biotech Stocks for Two Distinct investors
Via MarketBeat
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
3 Pharma Stocks' Post-Earnings Price Moves
Via MarketBeat
Topics ETFs Stocks
Exposures US Equities
7 Cheap Biotech Stocks to Buy Now
Via InvestorPlace
Recession Investing: 5 High Yield Dividend Stocks For A Downturn
Via Benzinga
Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study
Via Benzinga
Target And Chevron Get CNBC Fast Money Mentions With Joe Terranova Rebalancing His ETF
Via Benzinga
Peering Into AbbVie's Recent Short Interest
Via Benzinga
MarketBeat: Week in Review 7/25 – 7/29
Via MarketBeat
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Economy Interest Rates
Best Stocks To Hold For The Recession
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.